Vlacich Gregory, Stavas Mark J, Pendyala Praveen, Chen Shaeu-Chiann, Shyr Yu, Cmelak Anthony J
Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Current affiliation: Department of Radiation Oncology, Washington University School of Medicine, 4291 Parkview Place, Campus Box 63110, St. Louis, MO, 63110, USA.
Radiat Oncol. 2017 Jan 13;12(1):13. doi: 10.1186/s13014-016-0756-x.
Planning and delivery of IMRT for locally advanced head and neck cancer (LAHNC) can be performed using sequential boost or simultaneous integrated boost (SIB). Whether these techniques differ in treatment-related outcomes including survival and acute and late toxicities remain largely unexplored.
We performed a single institutional retrospective matched cohort analysis on patients with LAHNC treated with definitive chemoradiotherapy to 69.3 Gy in 33 fractions. Treatment was delivered via sequential boost (n = 68) or SIB (n = 141). Contours, plan evaluation, and toxicity assessment were performed by a single experienced physician. Toxicities were graded weekly during treatment and at 3-month follow up intervals. Recurrence-free survival, disease-free survival, and overall survival were estimated via Kaplan-Meier statistical method.
At 4 years, the estimated overall survival was 69.3% in the sequential boost cohort and 76.8% in the SIB cohort (p = 0.13). Disease-free survival was 63 and 69% respectively (p = 0.27). There were no significant differences in local, regional or distant recurrence-free survival. There were no significant differences in weight loss (p = 0.291), gastrostomy tube placement (p = 0.494), or duration of gastrostomy tube dependence (p = 0.465). Rates of acute grade 3 or 4 dysphagia (82% vs 55%) and dermatitis (78% vs 58%) were significantly higher in the SIB group (p < 0.001 and p = 0.012 respectively). Moreover, a greater percentage of the SIB cohort did not receive the prescribed dose due to acute toxicity (7% versus 0, p = 0.028).
There were no differences in disease related outcomes between the two treatment delivery approaches. A higher rate of grade 3 and 4 radiation dermatitis and dysphagia were observed in the SIB group, however this did not translate into differences in late toxicity. Additional investigation is necessary to further evaluate the acute toxicity differences.
局部晚期头颈癌(LAHNC)的调强放射治疗(IMRT)计划制定与实施可采用序贯推量或同步整合推量(SIB)。这些技术在包括生存率以及急性和晚期毒性等与治疗相关的结果方面是否存在差异,在很大程度上仍未得到探索。
我们对接受根治性放化疗、分33次给予69.3 Gy剂量的LAHNC患者进行了单机构回顾性匹配队列分析。治疗通过序贯推量(n = 68)或SIB(n = 141)进行。轮廓勾画、计划评估和毒性评估由同一位经验丰富的医生完成。在治疗期间每周以及在3个月的随访间隔时对毒性进行分级。通过Kaplan-Meier统计方法估计无复发生存率、无病生存率和总生存率。
4年时,序贯推量队列的估计总生存率为69.3%,SIB队列的为76.8%(p = 0.13)。无病生存率分别为63%和69%(p = 0.27)。局部、区域或远处无复发生存率无显著差异。在体重减轻(p = 0.291)、胃造瘘管置入(p = 0.494)或胃造瘘管依赖持续时间(p = 0.465)方面无显著差异。SIB组急性3级或4级吞咽困难(82%对55%)和皮炎(78%对58%)的发生率显著更高(分别为p < 0.001和p = 0.012)。此外,由于急性毒性,SIB队列中未接受规定剂量的百分比更高(分别为7%对0,p = 0.028)。
两种治疗实施方法在疾病相关结果方面无差异。SIB组观察到3级和4级放射性皮炎和吞咽困难的发生率更高,然而这并未转化为晚期毒性的差异。需要进一步研究以进一步评估急性毒性差异。